Abstracts tagged "Gene Expression and systemic lupus erythematosus (SLE)"

Abstract Number: 2835 • 2018 ACR/ARHP Annual Meeting
Association between Changes in Gene Signature Expression and Disease Activity in Systemic Lupus Erythematosus
Michelle Petri¹, Wei Fu¹, Ann Ranger², Normand Allaire², Patrick Cullen³ and Laurence S Magder⁴, ¹Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, ²Biogen Idec, Cambridge, MA, ³Biogen Idec, Cambridge, MD, ⁴Epidemiology and Public health, University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: We assessed the stability of BAFF, interferon, plasma cell and LDG neutrophil gene expression signatures over time, and whether changes in gene expression coincided…
Abstract Number: 1205 • 2016 ACR/ARHP Annual Meeting
In silico Drug Repurposing Analysis Supports Phosphoinositol 3 Kinase Inhibitors As Treatment of LUPUS
Daniel Toro¹, Pedro Carmona Sanz² and Marta Alarcón-Riquelme^3,4, ¹Bioinformatics and Medical Genomics, Center for Genomics and Oncological Research (GENYO), Pfizer-University of Granada-Andalusian Regional Government, Health Sciences Technology Park, Ganada, Spain, ²Unit of Bioinformatics, Center for Genomics and Oncological Research (GENYO), Pfizer-University of Granada-Andalusian Regional Government, Health Sciences Technology Park, Granada, Spain, ³Center for Genomics and Oncological Research (GENYO), Pfizer-University of Granada-Andalusian Regional Government, Health Sciences Technology Park, Granada, Spain, ⁴Unit for Chronic Inflammatory Diseases, Institute for Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a clinically heterogeneous disease with few treatment options. Current treatments are not fully effective and show highly variable responses.…
Abstract Number: 1865 • 2015 ACR/ARHP Annual Meeting
Association Between Changes in Expression of Gene Signatures and Disease Activity Among Patients with Systemic Lupus Erythematosus
Michelle Petri¹, Wei Fu², Ann Ranger³, Norm Allaire⁴, Patrick Cullen⁴ and Laurence S Magder⁵, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Biogen Inc., Cambridge, MA, ⁴Biogen Idec Inc., Cambridge, MA, ⁵University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: In recent work, we showed that a single measurement of several gene signatures in whole blood was associated with levels of disease activity at…
Abstract Number: 1868 • 2015 ACR/ARHP Annual Meeting
BLK Pathway-Associated rs13277113 GA Genotype Is More Frequent in Systemic Lupus Erythematosus Patients and Associated with Low Gene Expression and Increased Flares
Omer Nuri Pamuk¹, Hakan Gurkan², Mehmet Ali Balci¹, Hilmi Tozkir³, Julide Duymaz², Gülce Sari², Metin Yazar² and Gulsum Pamuk⁴, ¹Department of Rheumatology, Trakya University Medical Faculty, Edirne, Turkey, ²Trakya University Medical Faculty, EDIRNE, Turkey, ³Genetics, Trakya University Medical Faculty, EDIRNE, Turkey, ⁴Hematology, Trakya University Medical Faculty, Edirne, Turkey
Background/Purpose: It was reported that genetic variations in B cell signal transduction were associated with susceptibility to SLE. However, these studies were limited in number…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].